Limits...
Antibiotic resistance patterns in invasive group B streptococcal isolates.

Castor ML, Whitney CG, Como-Sabetti K, Facklam RR, Ferrieri P, Bartkus JM, Juni BA, Cieslak PR, Farley MM, Dumas NB, Schrag SJ, Lynfield R - Infect Dis Obstet Gynecol (2009)

Bottom Line: Clindamycin and erythromycin resistance was 12.7% and 25.6%, respectively, and associated with serotype V (P < .001).Erythromycin resistance increased from 15.8% to 32.8% (X(2) for trend 55.46; P < .001).While GBS remains susceptible to beta-lactams, resistance to alternative agents such as erythromycin and clindamycin is an increasing concern.

View Article: PubMed Central - PubMed

Affiliation: Infectious Disease Epidemiology, Prevention and Control Division, Minnesota Department of Health, Saint Paul, MN 55164, USA.

ABSTRACT
Antibiotics are used for both group B streptococcal (GBS) prevention and treatment. Active population-based surveillance for invasive GBS disease was conducted in four states during 1996-2003. Of 3813 case-isolates, 91.0% (3471) were serotyped, 77.1% (2937) had susceptibility testing, and 46.6% (3471) had both. All were sensitive to penicillin, ampicillin, cefazolin, cefotaxime, and vancomycin. Clindamycin and erythromycin resistance was 12.7% and 25.6%, respectively, and associated with serotype V (P < .001). Clindamycin resistance increased from 10.5% to 15.0% (X(2) for trend 12.70; P < .001); inducible clindamycin resistance was associated with the erm genotype. Erythromycin resistance increased from 15.8% to 32.8% (X(2) for trend 55.46; P < .001). While GBS remains susceptible to beta-lactams, resistance to alternative agents such as erythromycin and clindamycin is an increasing concern.

Show MeSH

Related in: MedlinePlus

Clindamycin and erythromycin resistance among invasive Group B streptococci isolates by state (n =  2 937 isolates).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2637368&req=5

fig2: Clindamycin and erythromycin resistance among invasive Group B streptococci isolates by state (n = 2 937 isolates).

Mentions: Significantdifferences were identified between Minnesota and New York isolates in clindamycin resistance (13.2% versus 9.3%, P = .03) anderythromycin resistance (24.5% and 31.4%, P < .01). Georgia isolates were more likely to beresistant to clindamycin than New York isolates (15.1% and 9.3%, P = .02), but Georgia isolates were less likely to be resistant to erythromycin than to New York isolates (26.3% and 31.4%, P = .04) (see Figure 2).


Antibiotic resistance patterns in invasive group B streptococcal isolates.

Castor ML, Whitney CG, Como-Sabetti K, Facklam RR, Ferrieri P, Bartkus JM, Juni BA, Cieslak PR, Farley MM, Dumas NB, Schrag SJ, Lynfield R - Infect Dis Obstet Gynecol (2009)

Clindamycin and erythromycin resistance among invasive Group B streptococci isolates by state (n =  2 937 isolates).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2637368&req=5

fig2: Clindamycin and erythromycin resistance among invasive Group B streptococci isolates by state (n = 2 937 isolates).
Mentions: Significantdifferences were identified between Minnesota and New York isolates in clindamycin resistance (13.2% versus 9.3%, P = .03) anderythromycin resistance (24.5% and 31.4%, P < .01). Georgia isolates were more likely to beresistant to clindamycin than New York isolates (15.1% and 9.3%, P = .02), but Georgia isolates were less likely to be resistant to erythromycin than to New York isolates (26.3% and 31.4%, P = .04) (see Figure 2).

Bottom Line: Clindamycin and erythromycin resistance was 12.7% and 25.6%, respectively, and associated with serotype V (P < .001).Erythromycin resistance increased from 15.8% to 32.8% (X(2) for trend 55.46; P < .001).While GBS remains susceptible to beta-lactams, resistance to alternative agents such as erythromycin and clindamycin is an increasing concern.

View Article: PubMed Central - PubMed

Affiliation: Infectious Disease Epidemiology, Prevention and Control Division, Minnesota Department of Health, Saint Paul, MN 55164, USA.

ABSTRACT
Antibiotics are used for both group B streptococcal (GBS) prevention and treatment. Active population-based surveillance for invasive GBS disease was conducted in four states during 1996-2003. Of 3813 case-isolates, 91.0% (3471) were serotyped, 77.1% (2937) had susceptibility testing, and 46.6% (3471) had both. All were sensitive to penicillin, ampicillin, cefazolin, cefotaxime, and vancomycin. Clindamycin and erythromycin resistance was 12.7% and 25.6%, respectively, and associated with serotype V (P < .001). Clindamycin resistance increased from 10.5% to 15.0% (X(2) for trend 12.70; P < .001); inducible clindamycin resistance was associated with the erm genotype. Erythromycin resistance increased from 15.8% to 32.8% (X(2) for trend 55.46; P < .001). While GBS remains susceptible to beta-lactams, resistance to alternative agents such as erythromycin and clindamycin is an increasing concern.

Show MeSH
Related in: MedlinePlus